100050 | 1400W - CAS 214358-33-5 - Calbiochem

100050
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmarDisponibilidad a confirmar
En existencia 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Ver precios y disponibilidad
      Click To Print This Page

      Descripción

      Replacement Information

      Tabla espec. clave

      Empirical FormulaCAS #
      C₁₀H₁₅N₃ · 2HCl 214358-33-5

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      100050-5MG
      Comprobando disponibilidad...
      Disponibilidad a confirmarDisponibilidad a confirmar
      En existencia 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente

          Ampolla de plást. 5 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Description
          OverviewA selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
          Catalogue Number100050
          Brand Family Calbiochem®
          SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
          References
          ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
          Product Information
          CAS number214358-33-5
          ATP CompetitiveN
          FormWhite solid
          Hill FormulaC₁₀H₁₅N₃ · 2HCl
          Chemical formulaC₁₀H₁₅N₃ · 2HCl
          Hygroscopic Hygroscopic
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetiNOS
          Primary Target IC<sub>50</sub>Kd = 7 nM against inducible nitric oxide synthase (iNOS)
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          Certificados de análisis

          CargoNúmero de lote
          100050

          Referencias bibliográficas

          Visión general referencias
          Parmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.

          Folleto

          Cargo
          Nitric Oxide and Oxidative Stress Brochure
          Pathways and Biomarkers of Oxidative Stress

          Citas

          Título
        • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.
        • Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision04-April-2011 RFH
          SynonymsN-(3-Aminomethyl)benzylacetamidine, 2HCl
          DescriptionA selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
          FormWhite solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number214358-33-5
          Chemical formulaC₁₀H₁₅N₃ · 2HCl
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityMethanol (5 mg/ml) or H₂O (1 mg/ml)
          Storage -20°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesParmentier, S., et al. 1999. Br. J. Pharmacol. 127, 546.
          Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
          Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
          Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
          Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
          Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
          Citation
        • Peyssonnaux, C., et al. 2005. The Journal of Clinical Investigation 115, 1860.